gonadotropin-releasing hormone agonist + gonadotropins

This combination therapy consists of a gonadotropin-releasing hormone (GnRH) agonist and exogenous gonadotropins. GnRH agonists are synthetic analogs of the natural hypothalamic hormone that initially stimulate, then desensitize, pituitary GnRH receptors, leading to suppression of endogenous luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion. This results in a hypogonadal state. When combined with exogenous gonadotropins—such as human menopausal gonadotropin, recombinant FSH or LH—the regimen allows for controlled ovarian stimulation by providing precise external control over follicular development and ovulation induction. This approach is widely used in assisted reproductive technologies like in vitro fertilization (IVF), where it increases oocyte yield, improves fertilization rates, and enhances pregnancy outcomes compared to conventional protocols[1][6]. The combination is also referred to as "superovulation therapy."